CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year.
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for November 8th
CRMD, FFIC and SPPJY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2024.
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q3 2024 Earnings Call October 30, 2024 8:30 AM ET Company Participants Dan Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Beth Zelnick Kaufman - Executive Vice President and Chief Legal Officer Liz Hulburt - Executive Vice President and Chief Clinical Strategy and Operations Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Conference Call Participants Jason Butler - Citizens JMP Gregory Renza - RBC Capital Brandon Folkes - Rodman & Renshaw Les Sulewski - Truist Securities Serge Belanger - Needham & Company Operator Good day and welcome to the CorMedix Inc. Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
CorMedix 2.0: New Leadership, New Approval, New Focus
CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath. The company has faced challenges in the past, including management issues and regulatory delays, but now warrants a fresh look and valuation as the company executes on commercialization. DefenCath offers a unique solution for preventing catheter-related bloodstream infections, with the potential to reduce costs and save lives.
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital +
The 'Undercovered' Dozen highlights 12 lesser-covered stock ideas from October 18th - 24th, offering fresh investment takes for community discussion. Dnis Buivolov updates their Nebius Group valuation; core business Nebius AI targets a $260 billion market by 2030, driven by AI infrastructure demand. ASP Isotopes' breakthrough in Ytterbium-176 enrichment positions it as a key supplier in high-margin radiopharmaceutical and nuclear fuel markets according to Sean Daly.
Here's Why CorMedix (CRMD) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know
Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think CorMedix (CRMD) Could Surge 117.77%: Read This Before Placing a Bet
The consensus price target hints at an 117.8% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
